HgCl₂ induces an autoimmune disease in the Brown Norway rat characterized by synthesis of autoantibodies (mainly, anti-GBM Abs), severe proteinuria and interstitial nephritis. Also, HgCl₂-injected rats develop glomerular cell infiltrates consisting of ED1 cells (monocyte/macrophage), starting on day 4 and reaching a maximum on day 8. Treatment with anti-TNF-α antiserum had preventative effects as it reduced the urinary protein levels to close to the normal range and also blocked the influx of inflammatory cells in the renal glomeruli and interstitium, but circulating anti-GBM and lineal glomerular IgG deposits were unmodified. In addition, whole isolated glomeruli from HgCl₂-induced nephritis secreted TNF commencing on day 8, being maximally detected on day 11 and preceding, between 2 to 3 days, the development of proteinuria. The administration of anti-TNF-α antiserum or anti-α4 integrin mAb completely abrogated the synthesis of TNF-α in glomeruli isolated from the respective treated groups of animals, in addition to the proteinuria. Taken together our results confirm that TNF-α plays an important role in the induction and development of HgCl₂-induced nephritis and highlights the pathogenic importance of the local release of TNF in those renal diseases in which prominent glomerular macrophage accumulation is a constant feature.

Key words: α4-integrin, glomerular macrophages, immunosuppression, mercury chloride, nephritis, proteinuria, TNF-α

Introduction

Mercuric chloride (HgCl₂) induces an autoimmune disease in the Brown Norway (BN) rat¹ mediated by T-dependent polyclonal B-cell activation⁶ resulting in hypergammaglobulinaemia, synthesis of anti-nuclear and anti-glomerular basement membrane (GBM) autoantibodies as well as development of nephritis with glomerular lineal deposits of Ig and proteinuria. The histological renal lesions consist of a transient influx of mononuclear cells (mainly MHC class II-bearing T-lymphocytes and monocytes) into the renal interstitium and monocytes and CD8⁺ T lymphocytes into the glomeruli.⁴ It has been shown recently that interaction between lymphocytes and endothelial cells (EC) is crucial in the development of this renal disease.⁵ Treatment with Abs against the α4-integrin abrogated the development of interstitial nephritis and virtually abolished the anti-GBM Abs production. Consequently, glomerular deposition of anti-GBM Abs was absent and proteinuria was reduced to levels close to the normal range. In contrast, anti-DNA Abs synthesis was unaffected by this treatment, suggesting a selective immunosuppressive role in the anti-α4-integrin Ab.

The role of lymphokines in leukocyte recruitment to inflammatory sites has been well documented. The increased expression of counter-receptors for leukocyte adhesion proteins, such as intercellular cell adhesion molecule (ICAM-1), endothelial cell adhesion molecule (ELAM-1) and vascular cell adhesion molecule (VCAM-1) on EC, has been identified in sites of inflammation, including target organs for autoimmunity.⁶⁻⁷ Cytokines (especially TNF-α, IL-1 and IFN-γ) activate endothelial cells to synthesize and to increase the expression of adhesion molecules and conversely, engagement of these molecules on the surface of such cells can induce and/or mediate cytokine expression.⁷⁻⁸ Recently, treatment of autoimmune diseases with cytokine agonists and their antagonists has been attempted in order to establish their clinical usefulness in the prevention of these disorders. Inflammatory mediators, such as TNF-α and IL-1β, have been...
Abrogation of mercuric chloride nephritis with anti-TNFα

Extensively investigated in autoimmune diseases and their potential pro-inflammatory effects demonstrated by increasing the severity of the glomerular injury in both rats and rabbits in the anti-GBM antibody mediated model of nephritis. In addition, in the renal cortices of lupus nephritic mice an enhancement of mRNA for TNF-α and IL-1β has been observed. Also, an augmented production of TNF has been demonstrated in the nephritic glomeruli in anti-GBM glomerulonephritis (GN). Moreover, it has been shown that the administration of anti-TNF antiserum abrogated the development of nephrotoxic nephritis in the rat. Taken together, these data suggest that TNF-α and IL-1β can be regarded as potential mediators of glomerular injury, playing an important role in the induction and development of renal autoimmune diseases.

The presence of both TNF-α and VLA-α4-integrin has proved to be necessary for the development of proteinuria and accumulation of inflammatory cells in other rat models of nephritis, unlike the requirements found in other models of renal diseases where complement and neutrophil-induced vascular injury are induced by deposition of immune complexes.

Using the experimental model of autoimmune renal disease described in this paper, we have examined in depth the required presence of TNF-α for circulating leukocyte accumulation (in both glomerular and renal interstitium) as well as in the development of proteinuria.

Materials and Methods

Animals: Brown Norway rats, weighing 180 to 200 g, were obtained from IFFA-CREDO (Paris, France) and from our own breeding colony, and maintained under standard conditions.

Antibodies: Rabbit anti-human TNF-α polyclonal antibody, which binds to human TNF-α and rat TNF-α, was obtained from Genzyme Co. (Cambridge, MA). The mouse anti-human HP2/1 mAb recognizes the VLA-α4-integrin and cross-reacts with the rat VLA-α4. This mAb blocks the interaction of both α4β1 and α4β7 integrins with its two known ligands, FN and VCAM-1. The following antibodies were purchased from Serotec (Oxford, UK): OX19, which recognizes the CD5 antigen; W3/25, which reacts with a subset of peripheral T cells expressing the CD4 antigen; OX8, which recognizes a stable determinant of the rat CD8 heterodimer; OX6 mAb, which recognizes the rat MHC class II antigens (RT1-B); and ED1 mAb, which reacts with rat macrophages.

Experimental procedure: Three groups of rats were injected s.c., three times a week, over a period of 2 weeks with 100 μg of HgCl2 per 100 g body wt. Animals from Group I (n = 20) did not receive any additional treatment. Rats belonging to Group II (n = 20) received an i.p. injection (25000 IU) of anti-TNF-α on days 0, 8 and 13 and those from Group III (n = 20) received an i.p. injection (0.5 mg) of HP2/1 mAb on days 0, 8 and 13. A fourth group (Group IV) (n = 20) served as a normal control in which rats were injected only with H2O adjusted to the same pH (3.8) as the HgCl2 solution, following the same procedure described above for the mercury administration. The dosages and days were established on the basis of previous optimizing experiments and our appreciation of the kinetics of the disease. All animals were sequentially bled on different days of the experiment by tail artery puncture. Four rats from each group were killed on days 4, 8, 11, 13 and 23 and kidneys were processed for study.

Proteinuria: Rats were maintained in metabolic cages for 24 h with free access to food and water. Urine samples were taken at regular intervals starting on day 0. Proteinuria was measured by using a Bio-Rad assay (Bio-Rad, Richmond, CA), according to the manufacturer’s protocol. Urine samples were assayed in triplicate. The OD from each sample was measured in a Titertek Multiskan Plus (Flow, Irvine, UK) at 595 nm.

Anti-GBM and anti-ssDNA Abs assay: Rat GBM was isolated, essentially, as described by Bowman et al. Briefly, glomeruli were obtained from normal BN rats by differential sieving and centrifugation of minced kidney cortices. The glomerular suspension was sonicated, washed and lyophilized. The GBM was digested with Type I collagenase (Sigma Chemical Co., St Louis, MO) at 0.7% w/w for 1 h at 37°C. Anti-GBM Abs were measured by ELISA as described previously. Anti-ssDNA Abs were measured by an ELISA developed in our laboratory. All the samples were assayed in quadruplicate.

Samples of a serum pool from untreated BN rats and from BN rats which were treated with HgCl2 and bled on day 13 of the disease served as negative and positive controls, respectively. Results were expressed as the percentage of binding obtained with samples from positive control serum.

Isolation and culture of glomeruli: Harvested kidneys from the four experimental groups of rats were decapsulated and the renal medulla removed. The dissected cortex was then minced.
with a razor blade in Hanks' balanced salt solution (HBSS) and sieved through decreasing pore size (250, 150 and 75 µm) as described previously. Glomeruli were finally collected on the top of a 75 µm sieve, with the suspension containing more than 95% of glomeruli free of tubular fragments. Preparations were suspended at a final concentration of 5000 glomeruli/ml in RPMI 1640 (Whittaker Bioproducts, Walkerville, MD) containing 10% (v/v) FCS (Flow), ampicillin (100 µg/ml) and streptomycin (100 µg/ml), and then incubated in 24-well plates (Nunc, Roskilde, Denmark) (5000 glomeruli/well) at 37°C in a 5% CO₂ atmosphere. Supernatants were harvested at 24 h, centrifuged at 100 g and stored at -20°C until assayed for the release of TNF.

All samples were screened for the presence of endotoxin by using the Limulus amoebocyte lysate (L.A.L.) assay (Whittaker). Briefly, dilutions were performed from standard endotoxin (0.5 to 0.03 E.U./ml, 1 E.U. = 0.1 ng/ml of endotoxin) as positive control as well as for our samples (using serial dilutions, 1:2 to 1:64). Non-pyrogenic water was used as negative control. All samples were assayed in quadruplicate. One hundred µl of L.A.L. (sensitivity, 0.1 E.U./ml) was added to each sample and then were incubated at 37°C for 1 h. The endotoxin concentration was obtained as the product of the lysate sensitivity per the 'limit point dilution' (the last dilution showing reaction with the L.A.L.). The limit of detection in the assay was 10 pg/ml, with all the samples screened showing less than 10 pg/ml.

**TNF-α assay:** The TNF-α activity was determined by standard MTT method on L929 cells (ATCC, Rockville, MD) in the presence of actinomycin D (1 µg/ml). Briefly, 3 x 10⁴ cells/well were resuspended in DMEM (Whittaker) containing 10% (v/v) FCS, ampicillin (100 µg/ml), streptomycin (100 µg/ml), and glutamine (10 mM) and further incubated overnight on flat-bottomed, 96-well plates (Nunc) at 37°C. Dilutions of supernatants from cultured glomeruli were added in triplicate. Also, half-log dilution of hrTNF (specific activity, 2 x 10⁹ to 2 x 10⁸ units/ml) (Genzyme) ranging from 200 µg/ml to 1 pg/ml was added to some wells to produce a standard curve. A 25 µl aliquot of MTT stock solution (5 mg/ml) was added to each of the wells and incubated for 4 h at 37°C. The supernatants were removed by careful aspiration and 200 µl of a 1:1 DMSO and ethanol mixture to solubilize the crystals was then added to each well. The plates were shaken gently and OD (to 595 nm) was determined using a Titrtek Multiskan Plus.

For neutralization studies, anti-TNF-α Ab or control sera were added simultaneously to wells containing 400 pg/ml of hrTNF-α (producing 50% lysis of 3 x 10⁴ L929 cells, in our experiments) or test samples, with a final concentration of 50% (v/v). This Ab neutralizes 2000 U of rtTNF-α. No TNF-α activity was found on L929 cells in those wells incubated with anti-TNF-α Abs.

Concentrations of TNF-α were extrapolated from a standard curve with known hrTNF-α dilutions. Results are expressed as pg/ml of TNF.

**Kidney tissue processing:** On days 13 and 23, rat kidneys (n = 4) from the groups I, II and IV were processed for histological and immunohistochemistry studies. For light microscopy, 3 µm paraffin-embedded kidney sections were stained with periodic acid–Schiffs (PAS). For immunohistochemistry studies, pieces of renal tissue were snap-frozen in isopentane precooled in liquid nitrogen, and stored at −70°C until used. Direct immunofluorescence studies were performed on ether/ethanol-fixed serial cryostat sections, by using FITC-conjugated rabbit anti-rat IgG (Sero tec), as described previously. In addition, the glomerular cell infiltrates were characterized in the kidneys of rats (n = 4) injected with mercury and in two control animals on days 4, 8, 13 and 23. These tissue kidneys were stained with an indirect immunophosphatase method (APAAP) using a panel of mAbs. The specificity of these mAbs was assessed by using normal serum, normal mouse IgG, and hybridoma-induced ascitic fluids containing unrelated Abs. Positive controls of the reagents were sections of normal rat spleen. These studies were performed by using a conventional light microscopy objective (x 63), as described previously.

**Statistical analysis:** The results are given as mean ± S.D. Values obtained from the levels of proteinuria and ELISA results were analysed using the Student’s t-test. For TNF assay, statistical analysis was performed by using a Wilcoxon rank-sum method for non-parametric significance testing.

**Results**

**Effect of anti-TNF-α treatment on the proteinuria:** As shown in Fig. 1, rats belonging to the Group I developed proteinuria in two different phases. A first short phase, which occurred immediately after the first injection of HgCl₂, due to the direct effect of mercury on tubular renal cells. This first phase was followed by a second phase starting on day 11 and declining after day 16 of the disease. On day 23, all the animals reached the background levels. When the rats
were treated with anti-TNF-α Ab (Group II), a drastic reduction (about 90%, \( p < 0.001 \)) in the urinary protein levels were found as compared with Group I (20.21 ± 7.99 mg/24 h vs. 128.04 ± 30.25 mg/24 h). The same effect was observed when rats were treated with anti-α4 integrin Abs (HP2/1 mAb). In both situations, the first phase of proteinuria was unaffected.

Effect of anti-TNF-α treatment on anti-GBM and anti-ssDNA synthesis: Increased anti-GBM Ab concentration in the serum from rats injected with mercury (Group I, Fig. 2A) was detected by ELISA from day 8, with the maximal concentration being observed on day 13 of the disease. After day 13, serum levels of anti-GBM Abs started to decline as also occurred with the proteinuria. The serum levels of anti-ssDNA Abs in this same Group I (Fig. 2B) showed a significant increase, first observed on day 4, but their kinetics of secretion were different from the anti-GBM Abs production.

In contrast to that found in BN rats treated with HP2/1 mAbs, which showed a significant (\( p < 0.001 \)) reduction in the anti-GBM Abs serum levels, the group of rats treated with anti-TNF-α Abs (Group II) presented circulating anti-GBM Abs levels similar to those found in Group I (HgCl2-injected rats) (Fig. 2A). All the groups analysed, with the exception of the negative control group (Group IV), showed the same kinetics as found in the anti-ssDNA Abs synthesis.
FIG. 3. Interstitial inflammatory cells accumulation in HgCl2-treated rats (Group I) (A) showing severe perivascular renal cell infiltrates. Group of rats treated with anti-TNF-α Abs (Group II) (B) shows the absence of inflammatory cells in the renal interstitium (PAS, ×20). Both groups (I and II) (C, IF × 500; and D, IF × 425, respectively) show positive linear GBM deposits of rat IgG.

(Fig. 2B). None of the treatments affected the ssDNA Abs production.

Histopathology and immunofluorescence studies on kidneys: Renal tissues from rats treated with HgCl2 (Group I) and HgCl2 plus anti-TNF-α Abs (Group II) (n = 4 rats/group), were examined by light microscopy on days 13 and 23 of the disease (Fig. 3A and B). As reported previously, kidney tissues from BN rats injected with mercury presented a severe interstitial mononuclear cell infiltrate. The inflammatory cells were preferentially located in the perivascular regions of the renal interstitium. However, in the same group of rats treated with anti-TNF-α Abs, cell infiltrates were not observed in the renal interstitium (Fig. 3B). Kidneys from H2O-injected rats showed a normal renal histology.

Phenotypic analysis of glomerular cell infiltrates are given in Table 1. We found an impor-

\begin{table}
\centering
\begin{tabular}{lcccc}
\hline
\multicolumn{5}{c}{Number of positive cellsglomerulus$^*$} \\
\hline
mAb & 0 & 4 & 8 & 13 & 23 \\
\hline
OX6 & 0.40 ± 0.07$^*$ & 0.65 ± 0.15 & 1.56 ± 0.60$^*$ & 1.53 ± 0.50$^*$ & 0.33 ± 0.15 \\
ED1 & 0.30 ± 0.06 & 0.67 ± 0.03$^*$ & 1.30 ± 0.28$^*$ & 0.50 ± 0.21 & 0.27 ± 0.10 \\
OX8 & 0.22 ± 0.07 & 0.20 ± 0.05 & 0.17 ± 0.06 & 0.70 ± 0.10$^*$ & 0.20 ± 0.03 \\
\hline
\end{tabular}
\caption{Glomerular leukocytes during HgCl2-induced nephritis}
\end{table}

$^*$Six rats, and two sections per rat were examined for each mAb. Twenty glomeruli were counted per section.

$^*$Result are expressed as mean ± S.D.

$^*$p < 0.01.
Abrogation of mercuric chloride nephritis with anti-TNF-α

**Group I (HgCl₂-injected)**

- Time (days): 0 4 8 11 13 23
- Proteinuria (mg/24h)
- TNF (ng/ml x 10^6)

**Group II (anti-TNF-α-treatment)**

- Time (days): 0 4 8 11 13 23
- Proteinuria (mg/24h)
- TNF (ng/ml x 10^6)

**Group III (HP2/1-treatment)**

- Time (days): 0 4 8 11 13 23
- Proteinuria (mg/24h)
- TNF (ng/ml x 10^6)

**FIG. 4.** TNF-α concentration from glomerular cultured supernatants. A. Glomerular TNF-α production (open bar) from HgCl₂-injected rats (Group I) and relationship between the development of proteinuria (●). B and C show the results obtained from glomerular cultured supernatants belonging to anti-TNF-α treated rats (Group II) and anti-α4 integrin (HP2/1)-treatment rats (Group III), respectively. Filled bar represents the TNF-α concentration from glomerular cultured supernatants from control rats (Group IV). Results shown represent the mean ± S.D. *p < 0.01, and **p < 0.05.

**Discussion**

The autoimmune disease induced in the BN rats by the injection of HgCl₂ is characterized by the synthesis of autoantibodies (mainly, anti-GBM Abs) due to a polyclonal B cell activation. The renal lesions consist of rat Ig deposition on the glomerular basement membrane with an influx of mononuclear cells and the development of proteinuria.1-4 The administration of anti-TNF-α antiserum to HgCl₂-injected rats significantly reduced the urinary protein levels but the synthesis of anti-GBM Abs as well as glomerular deposits of Ig remained unaffected. In addition, no infiltrating interstitial cells were found in this group of rats. These findings suggest that TNF-α plays an important role in the development of this renal injury, while autoimmune antibodies exist.14,15

The elevated serum production of autoantibodies observed after anti-TNF-α treatment strongly suggests that this antiserum acts mainly

Mediators of Inflammation · Vol 4 · 1995 449
at a local level. More evidence supporting this local anti-TNF-\(\alpha\) Abs effect was obtained when we studied the production of TNF-\(\alpha\) from isolated nephritic glomeruli. The glomeruli from HgCl\(_2\)-treated rats secreted TNF-\(\alpha\) between days 4–8 to the day 11 of the disease. Also, the studies carried out on the glomerular cell infiltrates in HgCl\(_2\)-injected rats demonstrated an influx of monocytes on day 4 of the disease with the highest number of infiltrating glomerular cells having been observed on day 8. On the other hand, an increase in the number of CD8\(^+\) lymphocytes was seen in the nephritic glomeruli on day 13. Moreover, the treatment with the anti-\(\alpha_4\) integrin mAb to HgCl\(_2\)-injected rats completely abrogated the secretion of TNF-\(\alpha\) from rat glomeruli. The \(\alpha_4\) integrin, an adhesion molecule expressed by almost all leukocytes, interacts with VCAM-1 (an endothelial pro-inflammatory inducible cell molecule), as well as with the alternative spliced form (CS-1) of FN, playing a central role in mediating leukocyte adhesion, extravasation, and migration to sites of inflammation.\(^{35,36}\) As has been previously demonstrated,\(^{37}\) the administration of anti-\(\alpha_4\) integrin mAb to HgCl\(_2\)-injected rats blocked the influx of circulating leukocytes into the renal interstitium and the accumulation of monocytes in the renal glomeruli. These data might suggest that infiltrating glomerular monocytes are the major source of glomerular TNF.

The results presented here are in agreement with those previously reported by Tipping et al.\(^{12}\) demonstrating the association between the glomerular monocyte infiltration and glomerular injury in anti-GBM nephritis. Nevertheless, the initial source of TNF in the glomerulus is still not entirely understood. It is well documented that resident glomerular cells can be responsible for TNF secretion. The stimulation of mesangial cells with LPS induces the synthesis of TNF-\(\alpha\),\(^{37}\) and the in vivo administration of LPS also induces glomerular TNF-\(\alpha\) mRNA expression in the absence of leukocyte cells infiltration.\(^{38}\) Also, it has been shown that stimulated resident glomerular macrophages have the facility to release cytokines such as IL-8, GM-CSF and TNF-\(\alpha\), among others.\(^{39}\)

It is well known that inorganic mercury remains a major environmental toxin that alters cell calcium homeostasis\(^{40}\) and mitochondrial functions.\(^{41}\) In concentrations commonly used in experimental models the Hg\(^{2+}\) acts as an ionophore as well as Cu\(^{+}\).\(^{42,43}\) In addition, the administration of HgCl\(_2\) causes the activation of circulating lymphocytes, resulting in a polyclonal B-cell activation\(^5\) and also producing a direct toxic effect on tubular renal cells. It is possible that mercury also has the potential to induce the activation of resident glomerular cells, thus initiating the secretion of cytokines as TNF-\(\alpha\). This local secretion of cytokines, in addition to stimulating chemotaxis, can induce the recruitment of circulating monocytes throughout the VLA-4/VCAM-1 cell adhesion pathway. The mechanism proposed could be supported based on the low levels of TNF-\(\alpha\) in the supernatants of cultured glomeruli and on the absence of renal tissue cell infiltrates after mercury-injected rats were treated with the anti-\(\alpha_4\) integrin.

References

7. Polser JS, Cotran RS. What can be learned from the expression of the endothelial adhesion molecules in tissue? Lab Invest 1991; 64: 301–305.


ACKNOWLEDGEMENTS. This work was supported by Grants 92/0420 and 95/1420 from the Fondo de Investigaciones Sanitarias (FIS), Spain. We thank Ms Carmen Masa, Ms Mela López, and Ms Rosa Ocaña for technical assistance. We are grateful to Ms Virginia Lynne Desbrow for her help in the manuscript correction.

Received 8 September 1995; accepted 16 October 1995